Aravax is a clinical-stage biotechnology company focused on developing innovative treatments for food allergies, particularly peanut allergies. The company employs a proprietary platform technology designed to reset the immune system's response to allergens, promoting tolerance without triggering severe allergic reactions. Their lead product, PVX108, has successfully completed Phase 1 clinical trials and is currently undergoing Phase 2 trials in adolescents and children. These trials aim to evaluate the safety and efficacy of PVX108 when administered intradermally in monthly doses over a year, with recruitment ongoing in both Australia and the United States.

The technology behind Aravax's approach centers on the modulation of allergen-specific T cells, which play a crucial role in regulating allergic responses. By identifying specific amino acid sequences from allergens that are recognized by human T cells, Aravax can design allergy-specific therapeutics that consist of peptide mixtures. These peptides do not contain the allergens that provoke acute reactions, allowing for repeated exposure in a non-inflammatory context. This method aims to shift the balance of T cells towards a protective phenotype, ultimately reducing allergic sensitization and restoring tolerance, similar to the natural process of "growing out" of allergies.

Australia

Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.

Aravax

Company Details